4/A//SEC Filing
Yeramian Patrick D 4/A
Accession 0000899243-23-009600
CIK 0001658551other
Filed
Mar 23, 8:00 PM ET
Accepted
Mar 24, 6:45 PM ET
Size
28.8 KB
Accession
0000899243-23-009600
Insider Transaction Report
Form 4/AAmended
Yeramian Patrick D
Chief Medical Officer
Transactions
- Award
Common Stock
2023-03-16+9,167→ 208,417 total - Award
Stock Option (right to buy)
2023-03-16+41,250→ 41,250 totalExercise: $32.08Exp: 2033-03-16→ Common Stock (41,250 underlying) - Exercise/Conversion
Common Stock
2023-03-16$0.33/sh+2,789$920→ 207,088 total - Exercise/Conversion
Common Stock
2023-03-16$0.37/sh+30,041$11,115→ 237,129 total - Exercise/Conversion
Stock Option (right to buy)
2023-03-16−30,041→ 62,466 totalExercise: $0.37Exp: 2029-03-18→ Common Stock (30,041 underlying) - Exercise/Conversion
Stock Option (right to buy)
2023-03-16−2,789→ 0 totalExercise: $0.33Exp: 2028-02-16→ Common Stock (2,789 underlying) - Exercise/Conversion
Stock Option (right to buy)
2023-03-16−16,748→ 48,252 totalExercise: $6.88Exp: 2031-02-21→ Common Stock (16,748 underlying) - Exercise/Conversion
Common Stock
2023-03-16$6.88/sh+16,748$115,226→ 253,877 total - Sale
Common Stock
2023-03-16$31.85/sh−52,211$1,662,842→ 201,666 total - Sale
Common Stock
2023-03-16$32.43/sh−2,416$78,358→ 199,250 total
Footnotes (9)
- [F1]On March 16, 2023, the Reporting Person filed a Form 4 (the "Original Form 4") which inadvertently omitted the exercise of an aggregate of 49,578 options by the Reporting Person. The Original Form 4 reported the sale of shares of Common Stock of the Issuer ("Common Stock") underlying those options, pursuant to a Rule 10b5-1 trading plan. This Form 4 amendment is being filed for the purpose of amending and restating the Original Form 4 solely to report the exercise of the stock options and the resulting increase in beneficial ownership of Common Stock. The Reporting Person has not sold any additional shares of Common Stock beyond those sales reported in the Original Form 4.
- [F2]These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 14, 2022.
- [F3]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $31.26 to $32.25. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
- [F4]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.28 to $32.93. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
- [F5]The reported transaction involves the Reporting Person's receipt of a restricted stock unit award (a "RSU"). The RSU shall vest in 4 equal annual installments, with the first installment vesting on the first day of the month of the one year anniversary of the date of grant, subject to the Reporting Person's continued service to the Issuer through such vesting date.
- [F6]1/4 of the shares subject to the option shall vest and become exercisable on the first day of the month of the one year anniversary of the date of grant, and the remaining shares shall vest monthly over the remaining 36 months, subject to the Reporting Person's continuous service to the Issuer through such vesting date.
- [F7]The shares subject to such option are vested and currently exercisable.
- [F8]As of the date of this filing, 39,688 shares subject to the option are vested and exercisable. 52,819 shares subject to such option vest and become exercisable in substantially equal monthly installments until November 26, 2023.
- [F9]16,256 shares underlying this option vested on February 19, 2022, with the remaining shares vesting in monthly installments of 1,354 shares thereafter.
Documents
Issuer
Amylyx Pharmaceuticals, Inc.
CIK 0001658551
Entity typeother
Related Parties
1- filerCIK 0001358266
Filing Metadata
- Form type
- 4/A
- Filed
- Mar 23, 8:00 PM ET
- Accepted
- Mar 24, 6:45 PM ET
- Size
- 28.8 KB